Displasia Fibrosa: studio epidemiologico e di correlazione tra dati antropometrici, clinici, trattamentali e genetici

Title

Code

DISPLASIA FIBROSA

Type

Sperimentale

Start Year

2022

Status

In Corso

Principal Investigator

051-6366519, 051-6366681

luca.sangiorgi@ior.it

Sangiorgi Luca, MD

Director

Rare skeletal disorders

Operational unit that carry out the study

complex unit

Malattie rare scheletriche

Director

Sangiorgi Luca, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta allo studio prot. DISPLASIA FIBROSA

Tuesday 19 July 2022, 17:03

PG0007905_2022_prot. DISPLASIA FIBROSA.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Displasia Fibrosa: studio epidemiologico e di correlazione tra dati antropometrici, clinici, trattamentali e genetici

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Displasia Fibrosa: studio epidemiologico e di correlazione tra dati antropometrici, clinici, trattamentali e genetici

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in